Watch AKBA. Know when insiders buy.
One email the day a filing lands. Free.
AKBA
Akebia Therapeutics, Inc.
0.98
−0.01 −0.81%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
24
FLAG · shorts 24
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $270.2MP/E —DIV YIELD —FCF YIELD 14.90%REV TTM $219.1M +7.5%NET INCOME −$29.7MNET CASH $106M52W 0.84 – 3.17SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $49.1M | −21.4% | 78.8% | −$6.3M | −$8.9M | −3706.5% | -0.03 | $3.5M | $1.1M | $2.4M | Aug 5 |
| Q1 2026 · Mar 31 | $53.5M | −6.6% | 77.0% | −$4.7M | −$9.1M | −248.1% | -0.03 | −$21.2M | $62K | −$21.3M | Aug 5 |
| Q4 2025 · Dec 31derived | $57.6M | +23.9% | 78.2% | −$8.6M | −$12.2M | — | -0.05 | $31.1M | $70K | $31.1M | Feb 26 |
| Q3 2025 · Sep 30 | $58.8M | +57.0% | 84.0% | $4.4M | $540K | — | 0.00 | $28.1M | $77K | $28M | Nov 10 |
| Q2 2025 · Jun 30 | $62.5M | +43.1% | 84.1% | $14.1M | $247K | — | 0.00 | $22.3M | $126K | $22.2M | Aug 5 |
| Q1 2025 · Mar 31 | $57.3M | +75.8% | 86.7% | $13.5M | $6.1M | — | 0.03 | −$13.6M | $18K | −$13.6M | Aug 5 |
| Q4 2024 · Dec 31derived | $46.5M | −17.3% | 56.2% | −$14.3M | −$22.8M | −3814.0% | -0.11 | −$4.5M | $2K | −$4.5M | Feb 26 |
| Q3 2024 · Sep 30 | $37.4M | −11.0% | 62.2% | −$12.5M | −$20M | — | -0.10 | −$6.7M | $2K | −$6.7M | Nov 10 |
| Q2 2024 · Jun 30 | $43.6M | — | 60.9% | −$8.7M | −$8.6M | — | -0.04 | −$10.1M | $29K | −$10.1M | Nov 10 |
| Q1 2024 · Mar 31 | $32.6M | — | 64.4% | −$14.9M | −$18M | — | -0.09 | −$19.4M | $0 | −$19.4M | Nov 10 |
| Q4 2023 · Dec 31derived | $56.2M | — | 66.8% | $1.4M | $614K | — | 0.00 | −$2.3M | $0 | −$2.3M | Feb 26 |
| Q3 2023 · Sep 30 | $42M | — | 57.2% | −$13M | −$14.5M | — | -0.08 | −$7.2M | $0 | −$7.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $236.2M | 83.3% | $23.5M | −$5.3M | -2.3% | -0.02 | $68M | $291K | $67.7M | — | — |
| FY2024 · to Dec 31 | $160.2M | 60.6% | −$50.5M | −$69.4M | -43.3% | -0.33 | −$40.7M | $33K | −$40.7M | — | — |
| FY2023 · to Dec 31 | $194.6M | 61.9% | −$46.3M | −$51.9M | -26.7% | -0.28 | −$23.4M | $0 | −$23.4M | — | — |
| FY2022 · to Dec 31 | $292.5M | 70.7% | −$80.8M | −$94.2M | -32.2% | -0.52 | −$73.2M | $114K | −$73.3M | — | — |
| FY2021 · to Dec 31 | $211.7M | 28.8% | −$264.5M | −$282M | -133.3% | -1.70 | −$253M | $59K | −$253M | — | — |
| FY2020 · to Dec 31 | $294.6M | -0.6% | −$377.8M | −$384.8M | -130.6% | -2.78 | −$110.4M | $317K | −$110.7M | — | — |
Every number comes from Akebia Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.